A molecule solves psoriasis?: Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses

被引:63
作者
Ghoreschi, K
Mrowietz, U
Röcken, M
机构
[1] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany
[2] Univ Schleswig Holstein, Dept Dermatol, Kiel, Germany
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2003年 / 81卷 / 08期
关键词
psoriasis; autoimmune disease; T helper cell 1; T helper cell 2; interleukin; 4;
D O I
10.1007/s00109-003-0460-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Psoriasis is an autoimmune disease affecting 2-4% of the Caucasian population. Inflammatory processes induce the migration of interferon (IFN) gamma producing Th1 lymphocytes into the skin. These play a key role in the pathogenesis of psoriasis. These Th1 lymphocytes are responsible for the pathological reactions in psoriatic skin leading to keratinocyte hyperproliferation, small vessel proliferation and neutrophilic infiltration. Antigen-presenting cells activate dermal CD4(+) T lymphocytes, and various signals can support the polarization of Th1 responses. The main signal for Th1 development is interleukin (IL) 12. After binding to their receptors both IL-12 and IFN-gamma promote intracellular IFN-gamma production by activating signal transducer and activator of transcription (STAT) 4 or 1. STAT1 activation by IFN-gamma is followed by T-bet activation, a master transcription factor for Th1 lymphocytes. In experimental models of Th1-mediated autoimmune diseases immune deviation of polarized autoreactive Th1 into anti-inflammatory Th2 responses generally improves the disease. Therefore new therapeutic approaches based on immunomodulating molecules have been developed for psoriasis, a prototypical Th1-mediated autoimmune disorder. Recently IL-4, the most effective Th2-inducing cytokine, has been shown to be safe and efficient for treating psoriasis. Improvement was associated with the induction of a Th2 phenotype of skin infiltrating lymphocytes. This review summarizes the IL-4 inducing potential of various conventional and newer systemic therapies for psoriasis. Many of these were thought to be primarily immunosuppressive. A review of the literature reveals that most of them can induce IL-4 and Th2, and that Th2 induction may be an underestimated mode of action in the therapy of Th1-mediated autoimmune disease. Further studies are needed to determine the central role of IL-4 in the control of Th1-induced autoimmune disease, namely psoriasis.
引用
收藏
页码:471 / 480
页数:10
相关论文
共 102 条
[71]   Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis [J].
Prinz, JC .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (04) :326-332
[72]  
RACKE MK, 1995, J IMMUNOL, V154, P450
[73]   CYTOKINE-INDUCED IMMUNE DEVIATION AS A THERAPY FOR INFLAMMATORY AUTOIMMUNE-DISEASE [J].
RACKE, MK ;
BONOMO, A ;
SCOTT, DE ;
CANNELLA, B ;
LEVINE, A ;
RAINE, CS ;
SHEVACH, EM ;
ROCKEN, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (05) :1961-1966
[74]   Transcription factors of the NFAT family: Regulation and function [J].
Rao, A ;
Luo, C ;
Hogan, PG .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :707-747
[75]   Promoter polymorphisms of the genes encoding tumor necrosis factor-α and interleukin-1β are associated with different subtypes of psoriasis characterized by early and late disease onset [J].
Reich, K ;
Mössner, R ;
König, IR ;
Westphal, G ;
Ziegler, A ;
Neumann, C .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 118 (01) :155-163
[76]   Treatment of psoriasis with interleukin-10 [J].
Reich, K ;
Brück, M ;
Gräfe, A ;
Vente, C ;
Neumann, C ;
Garbe, C .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (06) :1235-1236
[77]   Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology [J].
Reynolds, NJ ;
Al-Daraji, WI .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2002, 27 (07) :555-561
[78]   IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease [J].
Rocken, M ;
Racke, M ;
Shevach, EM .
IMMUNOLOGY TODAY, 1996, 17 (05) :225-231
[79]   INFECTION BREAKS T-CELL TOLERANCE [J].
ROCKEN, M ;
URBAN, JF ;
SHEVACH, EM .
NATURE, 1992, 359 (6390) :79-82
[80]   ANTIGEN-SPECIFIC ACTIVATION, TOLERIZATION, AND REACTIVATION OF THE INTERLEUKIN-4 PATHWAY IN-VIVO [J].
ROCKEN, M ;
URBAN, J ;
SHEVACH, EM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (06) :1885-1893